Trials / Completed
CompletedNCT00743067
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1363089 (formerly XL880) | GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally |
Timeline
- Start date
- 2006-08-09
- Primary completion
- 2009-05-02
- Completion
- 2009-11-09
- First posted
- 2008-08-28
- Last updated
- 2017-07-26
Source: ClinicalTrials.gov record NCT00743067. Inclusion in this directory is not an endorsement.